In what they claim is the first large-scale systematic analysis of thousands of gene fusions in human cancers, scientists have identified a gene fusion that could represent a novel drug target for multiple cancers. Through their studies, the largely U.K.-based … Read more
According to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive. The study, published … Read more
By Jessica Kent
A system-based intervention reduced racial disparities among black and white cancer patients.
A pragmatic, system-based intervention decreased racial disparities in cancer treatment and outcomes for black patients with early-stage breast cancer.
In a five-year study conducted at … Read more
By Michael Brown
Oncologists may soon have an accurate and inexpensive way of differentiating between types of ovarian cancer that will improve how patients are treated, thanks to findings from a national research study co-led out of the University of … Read more
By Kristin Jenkins
The presence of a BRCA germ line mutation in patients with invasive epithelial ovarian cancer may confer a short-term survival advantage, but is not associated with a reduction in long-term mortality, researchers found.
A follow-up study comparing … Read more
DNA shed by tumors into the bloodstream is starting to be used for the early detection of cancer and for monitoring how well treatment is working. Such DNA, which is called circulating tumor DNA (ctDNA), hasn’t been quite as helpful… Read more
A team of researchers at UCLA’s Jonsson Comprehensive Cancer, Cedars-Sinai Cancer and Dana-Farber Cancer Institute have newly identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer. The findings, published today in … Read more
A systematic examination of the tumor and the tissue surrounding it—particularly normal cells in that tissue, called fibroblasts—has revealed a new treatment target that could potentially prevent the rapid dissemination and poor prognosis associated with high-grade serous carcinoma (HGSC), a … Read more
Given that the limited number of patients and differences in biologic behavior pose challenges in conducting clinical trials in rare malignancies, researchers determined whether using genomic profiling for rare gynecologic malignancies is feasible and have clinical utility. They analyzed somatic… Read more
By Anne Trafton… Read more
Research carried out at the University of Tartu Faculty of Medicine used nanoparticles for the development of new imaging and treatment methods for peritoneal cancers. Tests showed that precision-guided anticancer nanoparticles have improved efficacy and reduced side effects.
One of … Read more
By Beth Fand Incollingo and Kristie L. Kahl
Patients with ovarian cancer tend to underreport their most challenging symptoms; however, an analysis of their online comments could give health care providers insight into how to help.
A machine learning approach … Read more
By Krista Conger
A large study of women with breast and ovarian cancer has revealed significant gaps between national guidelines for genetic testing and actual testing practices, according to researchers from Stanford and five other institutions.
Fewer than a quarter … Read more
“The longer the history of oral contraceptive use, the greater the protection we observed in terms of reduced chance of dying from aggressive ovarian cancer,” said study first author Jennifer Mongiovi.
The protection that birth control pills offer against ovarian … Read more
By Christina Bennett, MS
Women at increased risk for hereditary ovarian cancer who underwent risk-reducing salpingo-oophorectomy experienced less worry but worse menopausal symptoms and more regret compared with those who underwent salpingectomy with delayed oophorectomy, the Women Choosing Surgical Prevention … Read more
A team of researchers across The University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.
The Cancer Research UK and Wellcome Trust funded study, published in the journal Cancer Cell… Read more
By Kristie L. Kahl
Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose, according to a recent analysis… Read more
By Ian Ingram
Study identifies subgroup for whom another go could be worthwhile.
Lack of response to a PARP inhibitor in epithelial ovarian cancer didn’t necessarily mean patients were resistant to all such agents, a small retrospective study indicated.
Among … Read more
By Ian Ingram
In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.
Compared with placebo, … Read more
Since tumors often have unique defects in the DNA damage response (DDR) pathway, identifying the molecular mechanisms that underlie how cells repair various DNA lesions is critical to selecting the appropriate clinical treatments. Inhibitors to poly-(ADP-ribose) polymerase (PARP) are examples … Read more